Device Firms Eye Rocketing Pay-For-Performance Insurance Plans Warily
This article was originally published in The Gray Sheet
Industry group AdvaMed says it is concerned a rapid shift toward pay-for performance and financial risk-sharing models by commercial insurers will discourage providers from giving patients newer devices and could stifle innovation.
You may also be interested in...
Although CMS’ newly finalized rule on accountable care organizations has allayed health care providers’ fears of a program too burdensome to bother with, medical device manufacturers remain worried that ACOs will curb patient access to their products.
Amunix’s XTEN technology for half-life extension and precise drug delivery has been used by multiple partners over the past 15 years, but now the firm is building its own cancer therapy pipeline.
Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. Thirty-eight guidance documents have been posted on the tracker since its last update.